TO-O-1002 / Metagone Biotech - LARVOL DELTA

A Phase IIa Study of A Novel Non-Invasive Treatment, TO-O-1002, in nAMD Patients (ARVO 2024) - P2 | "This study demonstrated the potential of TO-O-1002 as a noninvasive option for the treatment of nAMD. Rescue-free data indicated that 86% patients unnecessary to receive IVT within 12 weeks of IP treatment, and most patients express more willingness to keep using study eye drops for long-term treatment. TO-O-1002 also allows patients to self-administer at home, which greatly reduces the burden placed on care-givers."

Clinical • P2a data • Age-related Macular Degeneration • Diabetic Macular Edema • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD) (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Theratocular Biotek Co. | Trial completion date: Dec 2023 ➔ Mar 2024 | Trial primary completion date: Dec 2023 ➔ Mar 2024

Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD) (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Theratocular Biotek Co. | Not yet recruiting ➔ Recruiting | Trial completion date: Feb 2023 ➔ Oct 2023 | Trial primary completion date: Feb 2023 ➔ Oct 2023

Enrollment open • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration